Bristol-Myers Squibb and Pfizer reported negative preliminary results from a phase III trial of apixaban for the prevention of venous thromboembolism (VTE)

Source :: CenterWatch Weekly. September 2, 2008, Vol. 12 Issue 35, p7, 1 p.
Publication Year :: 2008
Abstract: Bristol-Myers Squibb and Pfizer reported negative preliminary results from a phase III trial of apixaban for the prevention of venous thromboembolism (VTE). This study, dubbed ADVANCE-1, enrolled 3,000 subjects undergoing [...]

Subjects :: Pfizer Inc. -- Research
Bristol-Myers Squibb Co. -- Research
Thrombophlebitis -- Drug therapy -- Research
Anticoagulants (Medicine) -- Research -- Dosage and administration -- Health aspects
Pharmaceutical industry -- Research -- Health aspects
Health

Tools